2020-2027 Analysis and Review Temozolomide Market

Temozolomide Market

Temozolomide Market by Clinical Application (Anaplastic Astrocytoma, Glioblastoma Multiforme and Others) by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

26-07-2020 REP-HC-5144 40 Tables 120 pages Format

The temozolomide market was valued at USD 182.2 Mn by 2019. The rising prevalence of brain cancer worldwide primarily drives the temozolomide market growth. Furthermore, the effective implementation of the treatment guidelines pertaining to the management and treatment of malignant brain tumors further accentuates the market growth.

Temozolomide Market

Temozolomide is classified as an antineoplastic drug that is widely used by a neurologist for the treatment of refractory anaplastic astrocytoma. It is basically not active unless it is converted into MTIC at physiological pH and is reported to alkylate the DNA at the O3 position of adenosine, N7 position of guanine, and O6 position of guanosine, etc. It has a complete and rapid absorption via the gastrointestinal tract and has a half-life of approximately 1.8 hours.

The major segments related to the temozolomide market are: 

By Clinical Application (2017–2027; US$ Mn)

Anaplastic Astrocytoma

Glioblastoma Multiforme

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global Temozolomide market
  • The overall segmentation of the temozolomide market, by clinical application, distribution channel, and geography is minutely studied. Anaplastic astrocytoma and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • Growing inicidence of brain cancer worldwide
  • Effective implementation of the treatment guidelines pertaining to the management of brain cancer further accentuates the market growth

Report gist?

  • The study of the global temozolomide market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of temozolomide due to the  rising prevalence of brain cancer worldwide
  • The report will benefit healthcare professionals prescribing temozolomide for the effective management of brain cancer across the globe
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to temozolomide market
  • Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Glioblastoma multiforme is spearheading the clinical application segment for temozolomide market on account of the inherent resistance to conventional therapy and abnormal migration of malignant astrocytes in the adjacent brain tissues due to the increased intracranial hypertension. It accounts for 52% of all primary brain tumors. Anaplastic astrocytoma is considered a rare malignant brain tumor that arises from the astrocytes which is a supportive cell of the nervous system. According to the latest information provided by the American Cancer Society (ACS), anaplastic astrocytoma accounts for 1% to 2% of the primary brain tumors worldwide. There are different subtypes of anaplastic astrocytoma which are recognized by the abnormal genetic signatures such as IDH mutants and IDH wildtype.

Hospital pharmacy is currently leading the distribution channel segment for the temozolomide market. The drug-related severe adverse events associated with temozolomide such as constipation, nausea, vomiting, skin rash, etc. make it mandatory for precise drug compounding under the medical supervision of a hospital pharmacist. Retail pharmacy is expected to register exemplary market growth in the near future on account of the flourishing generic drugs market and its ability to cater to the medicinal requirements of households residing in remote locations.

North America is presently representing the largest market share in the geography segment for the temozolomide market. The rising prevalence of brain cancer primarily drives market growth in the region. As per the latest research citings presented by the American Society of Clinical Oncology (ASCO), in 2020 approximately 23,890 adults in the United States were suffering from diagnosed with cancerous tumors of the brain and spinal cord. Furthermore. The nurturing regulatory environment provided by the USFDA for the sale and distribution of temozolomide products further accentuates the market growth in the region. Europe is considered as the second-largest regional segment for temozolomide market on account of the affordable reimbursement scenario for temozolomide drug formulations in the region. Additionally, the effective implementation of the treatment guidelines postulated by the European Society of Molecular Oncology (ESMO), pertaining to the management and treatment of brain cancer propels the market growth in the region. The Asia Pacific is anticipated as the fastest growing regional segment for the temozolomide market. Developing healthcare infrastructure and lucrative market opportunities for western giants to establish subsidiaries and retail outlets together determine the temozolomide market growth.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.